Lupi-Herrera E, González PH, Juárez HU, Chuquiure E, Vieyra G, Martínez SC

Language: Spanish
References: 209
Page: 311-349
PDF size: 957.41 Kb.

ABSTRACT

Treatment for ST- elevation acute coronary syndromes (acute myocardial infarction: AMI) has advanced rapidly in the last decade with major improvements in early fibrinolytic therapy (FT), primary percutaneous interventions (PCI) with the aid of platelet glycoprotein IIb/IIIa inhibitors. Recent interest has shifted from infarct related artery (IRA) patency to microvascular perfusion in the evaluation of patients with AMI. It is well known that establishing epicardial patency after AMI (TIMI 3 E) is not synonymus with tissue-level perfusion (TIMI 4M). Microvascular dysfunction due to the roles of platelet and inflammatory mediators in the no-reflow phenomenon occurs in a substancial proportion of patients despite thrombolytic therapy or PCI procedures. Techniques are now available that measure real tissue–level perfusion and also therapy is directed to optimize myocardial perfusion in patients with AMI. Despite advances, contemporary FT strategies with the combination of platelet glycoprotein IIb/IIIa inhibitors restore normal coronary flow (TIMI 3) in the IRA in only 50-75% and PCI achieves TIMI 3 flow rates in 90-95%, but only with modest reductions in mortality, but with significant reductions in rethrombosis of the IRA or stents, reinfarctions and in some patients with benefits in ventricular dysfunction. Therefore moving beyond the importance of TIMI 3 flow, the TIMI 4 flow, or improving tissue-level perfusion in the setting of AMI seems to be the paradigm for the treatment of ST-elevation acute coronary syndromes.

REFERENCES

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al: ACC/AHA guidelines for the managements of patients with unstable angina and non-ST segment elevation MI: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina ). J Am Coll Cardiol 2000; 36: 970–1062.

2. Antman EM, Bassand JP, Klein W, Ohman M, López Sendón JL, Rydén L et al: Myocardial Infarction redefined–a cosensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36:959-69.

3. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N: Ability of minor elevations of troponins I and T to predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial Infarction. Results From a Randomized Trial. JAMA 2001; 286: 2405–2412.

4. Quin JM, Moliterno DJ: Troponins in Acute Coronary Syndromes. More TACTICS for an Early Invasive Strategy. JAMA 2001; 286: 2461-62.

5. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L, e investigadores del FRISC II: Mechanisms Behind the prognostic Value of Troponin T in Unstable Coronary Artery Disease: A FRISC II Substudy. J Am Coll Cardiol 2001; 38: 979-86.

6. Antman EM: Troponin Measurements in Ischemic Heart Disease: More Than Just a Black and White Picture. J Am Coll Cardiol 2001; 38: 987-90.

7. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G et al: The TIMI risk score for unstable angina–non ST-elevation MI: a method for prognostication and therapeutic decision-making. JAMA 2000; 284: 835-42.

8. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E: An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTMI in PRISM-PLUS. Eur Heart J 2002; 23: 223-229.

9. Langer A, Goodman SG, Topol E, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW: Late assessment of Thrombolytic Efficacy (LATE ) Study: Prognosis in Patients With Non-Q wave Myocardial Infarction. J Am Coll Cardiol 1996; 27: 1327–32.

10. Fibrinolytic Therapy Trialist (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994; 343: 311-22.

11. ISIS Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 1,7187 cases of suspected myocardial infarction. Lancet 1988; 2: 349-360.

12. Farmer JA: Aggressive Lipid Therapy in the Statin Era. Progr Cardiovasc Dis 1998; 41: 71–94.

13. TIMI Research Group: Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA 1988; 260: 2849–2858.

14. Lenderink T, Simoons ML, Van Es GA, Van de Werf F, Verstrate M, Arnold AER: Benefit of Thrombolytic Therapy Is Sustained Throughout Five Years and Is Related to TIMI Perfusion Grade 3 But not Grade 2 Flow at Discharge. Circulation 1995; 92: 1110–1116.

15. Weber KT, Clark WA, Janicki JS, Shroff SG: Physiologic versus pathologic hypertrophy and the pressure-overload myocardium. J Cardiovasc Pharmacol 1987; 10 ( Suppl. 6 ): s37-s50.

16. Hoffman JI: Heterogeneity of myocardial blood flow. Basic Res Cardiol 1995; 90: 103–111.

17. Vetterlein F, Prange M, Lubrich D, Pedina J, Neckel M, Schmidt G: Capillary perfusion pattern and microvascular geometry in heterogeneous hypoxic areas of hypoperfused rat myocardium. Am J Physiol 1995; 268: H 2183–H 2194.

18. Schemermund A, Bell MR, Lerman LO,Ritman EL, Rumberger JA: Quantitative evaluation of regional myocardial perfusion using fast X-ray computed tomography. Herz 1997; 22: 29–39.

19. Schelbert HR: Cardiac PET; microcirculation and substrate transport in normal and disease human myocardium. Ann Nuclear Med 1994; 8: 91–100.

20. Gavin BJ, Maxwell L, Edgar S: Microvascular Involvement in Cardiac Pathology. J Mol Cell Cardiol 1998; 30: 2531-2540.

21. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB: The wavefront phenomenon of ischemic cell death I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794.

22. Schaper W: Angiogenesis in the adult heart. Basic Res Cardiol 1991; 86 (Suppl, 2): 51-56.

23. Hoffman JI, Spaan JA: Pressure–flow relations in coronary circulation. Physiol Rev 1990; 70: 331–390.

24. Jantunen E, Collan Y: Transmural differenes in ischaemic heart disease: a quantitative histologic study. Appl Pathol 1989; 7: 179–187.

25. Hoyt JC, Hutchins GM: Variceal transformation of the subendocardial microvasculature in regions of chronic myocardial ischemia. Am Heart J 1989; 117: 830–836.

26. Zielinski KW, Kulig A: Histomorphometric investigations of the human heart microvasculature in coronary disease. Patologia Polska 1994; 45: 17–28.

27. Kelm M, Schafer S, Preik M, Schoebel FC, Preik-Steinhoff H, Strauber BE: Coronary Vasomotion in coronary heart disease–significance of epicardial and microcirculatory vessels from myocardial perfusion. Z Kardiol 1997; 86 (Suppl. 1): 33-41.

28. Hearse DJ, Maxwell L, Saldanha C, Gavin JB: The myocardial vasculature during ischemia and reperfusion: a target for injury and protection. J Moll Cell Cardiol 1993; 25: 759–800.

29. Gavin JB, Humphrey SM, Herdon PB: The no reflow phenomenon in ischaemic myocardium. Int Rev Expt Pathol 1983; 25: 361-383.

30. Kloner RA, Ganote CE, Jennings RB: The “no reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496–1508.

31. Sage MD, Gavin JB: Microvascular function at the margins of early experimental infarcts in isolated rabbit hearts. Heart Vessels 1986; 2: 81–86.

32. Michaels AD, Gibson CM, Barron HV: Microvascular Dysfunction in Acute Myocardial Infarction: Focus on the Roles of Platelet and Inflammatory Mediators in the No-Reflow Phenomenon. Am J Cardiol 2000; 85: 50B-60B.

33. Dreyer W, Michael L, West M: Neutrophil accumulation in ischemic canine myocardium: insights into the time course, distribution, and mechanism of localization during early reperfusion. Circulation 1991; 84: 400–11.

34. Kloner RA, Giacomelli F, Alker KJ, Mathews R, Bellows S: Influx of neutrophils into the walls of large coronary arteries in response to ischemia/reperfusion. Circulation 1991; 84: 1758–1772.

35. Sheridam FM, Cole PG, Ramage D: Leucocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model. Circulation 1996; 93: 1784–1787.

36. Engler RL, Schmith-Schonbein GW, Pavelec RS: Leucocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111: 98–111.

37. Siminiak T, Egdell RM, O’ Gorman DJ, Dye JF: Plasma–mediated neutrophil activation during acute myocardial infarction: role of platelet activating factor. Clin Sci 1995; 89: 171–176.

38. Kukielka GL, Smith CW, Manning AM, Yourker KA, Michael LH, Entman ML: Induction of interleukin-6 synthesis in the myocardium: potential rle in post-reperfusion inflammatory injury. Circulation 1995; 92: 1866–1875.

39. Frangogiannis NG, Yourker KA, Rossen RD; Gwechenberger M, Lindsey MH, Mendoza LH et al: Cytoquines and the microcirculation in ischemia and reperfusion. J Mol Cell Cardiol 1998; 30: 2567–2576.

40. Romsom JL, Hook BG, Kunel SL, Abrams GD, Schork A, Lucchesi BR: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983; 67: 1016–1023.

41. Yasuda M, Takeuchi K, Hiruma M, Iida H, Tahara A, Itagane H et al: The complement system in ischemic heart disease. Circulation 1990; 81: 156–163.

42. Langlois PF, Gawryl MS: Detection of the terminal complement complex in patients plasma following acute myocardial infarction. Atherosclerosis 1988; 70: 95–105.

43. Giclas PC, Pinckard RN, Olson MS: In vivo activation of complement by isolated heart subcellular membranes. J Immunol 1979; 122: 146–151.

44. Pinkard RN, O’Rourke RA, Crawford MH: Complement localization and mediation of ischemic injury in balloon myocardium. J Clin Invest 1983; 66: 1050–1056.

45. Fletcher MP, Stahl GL, Longhurst JC: C5a–induced myocardial ischemia: role for CD18-dependent PMN localization and PMN–platelet interactions. Am J Physiol 1993; 265: H 1750–H 1761.

46. Weyrich AS, Ma XL, Lefer DJ; Albertine KH, Lefer AM: In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993; 91: 2620–2629.

47. Shimomura H, Ogawa H, Arai H, Moriyama Y, Takazoe K, Hirai N et al: Serial changes in plasma level of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol 1998; 81: 397–400.

48. Brown KK, Henson PM, Maclouf J, Moyle M, Ely JA, Worthen GS: Neutrophil–platelet adhesion: relative roles of platelet-P selectin and neutrophil b2 (CD 18) integrins. Am J Respir Cell Moll Biol 1998; 18: 100–110.

49. Sheikh S, Nash GB: Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets. Blood 1996; 87: 5040–5050.

50. Perez RG, Arai M, Richardson C, DiPaula A, Siu C, Matsumoto N et al: Factors modifying protective effect of anti-CD 18 antibodies on myocardial reperfusion injury in dogs. Am J Physiol 1996; 270: H53-H64.

51. Engler RL: Free radical and granulocyte–mediated injury during myocardial ischemia and reperfusion. Am J Cardiol 1989; 63: 19E–23E.

52. Kloner RA: Does reperfusion injury exist in humans? J Am Coll Cardiol 1993; 21: 537–545.

53. Entman ML, Youker K, Shoji T, Kukiela G, Shappel SB, Taylor AA: Neutrophil induced oxidative injury of cardiac myocites: a compartmented system requiring CD 11/CD18-ICAM-1 adherence. J Clin Invest 1992; 90: 1335-1345.

54. Pryzklenk K, Kloner RA: Superoxide dismutasa plus catalasa improve contractile function in the canine model of the “stunned myocardium”. Circ Res 1986; 58: 148–156.

55. Hansen PR: Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872–1885.

56. Lucchesi BR: Modulation of leucocyte–mediated myocardial reperfusion injury. Ann Rev Physiol 1990; 52: 561-576.

57. De Scheerder IK, VandeKraay AMM, Lamers JMJ, Koster JF, de Jong JW, Serruys PW: Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanism for free radical generation. Am J Cardiol 1991; 68: 392–395.

58. Roberts MJ, Young IS, Trouton TG, Trimble ER, Khan MM, Webb SW et al: Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990; 336: 143–145.

59. Davies SW, Ranjadayalan K, Wickens Dg, Dorurandy TL, Timmis AD: Lipid peroxidation associated with successful thrombolysis. Lancet 1990; 335: 741–743.

60. Forman MB, Perry JM, Wilson BH; Verani MS, Kaplan PR, Shawl FA, Fresinger GC: Demonstration of myocardial reperfusion injury in humans: results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction. J Am Coll Cardiol 1991; 18: 911–918.

61. Wall T, Califf R, Blankenship J: Intravenous Fluosol in the treatment of acute myocardial infarction: results of the Thrombolysis in myocardial infarction 9 Trial. Circulation 1994; 90: 114–120.

62. Werns SW, Brinker J, Gruber J, Rothbaum D, Heuser R, George B et al: A randomized double blind trial of recombinant human superoxide dismutasa (SOD) in patients undergoing PTCA for acute MI. Circulation 1989; 80 (Suppl. II) II-113.

63. Flaherty JT, Pitt B, Gruber JW, Heuser RR, Rothbaum D, Burwell LR, et al: Recombinant human superoxide dismutasa (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994; 89: 1982–1991.

64. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, et al: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 study Group. J Am Coll Cardiol 1989; 14: 877–884.

65. Topol EJ, Yadav JS: Recognition of the importance of embolization in Atherosclerotic Vascular Disease. Circulation 2000; 101: 570–580.

66. Abdelmeguid AE, Topol EJ: The myth of the myocardial “infarctlet” during percutaneous coronary revascularization procedures. Circulation 1996; 94: 3369–3375.

67. Kloner RA, Arimie RB, Kay GL, Cannom D, Matthews R, Bhandari A, et al: Evidence for stunned myocardium in humans: a 2001 update. Coron Artery Dis 2001; 12: 349–356.

68. Kloner RA, Przyklenk K, Whittaker P: Deleterious effects of oxygen radicals in ischemia/reperfusion: resolved and unresolved issues. Circulation 1989; 80: 1115–1127.

69. Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML: Reduction in experimental infarct size by recombinant human superoxide dismutasa: insights into the pathophysiology of reperfusion injury. Circulation 1986; 74: 1424–1433.

70. Becker LC, Schaper J, Jeremy R, Schaper W: Severity of ischemia determines the occurrence of myocardial reperfusion injury. Circulation 1991; 84 (Suppl II): II-254.

71. Ganz W, Watanabe I, Kanamasa K, Yano J, Han DS, Fishbein MD: Does reperfusion extend necrosis? A study in a single territory of myocardial ischemia–half perfused and half no reperfused. Circulation 1990; 82: 1020–1033.

72. Kloner RA, Przyklenk K: Experimental infarct size reduction with calcium channel blockers. J Am Coll Cardiol 1991; 18: 876–878.

73. Olafson B, Forman MB, Puett DW: Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987; 76: 1135–1145.

74. DeGraeff PA, Van Gilst WH, Bel K, De Langen CDJ, Kingma JH, Wesseling H: Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed-chest pig model. J Cardiovasc Pharmacol 1987; 9 (Suppl. 2):537–542.

75. 75, Nabel EG, Topol EJ, Galeana A: A randomized placebo–controlled trial of combined early intravenous captopril and recombinant tissue–type plasminogen activator in acute myocardial infarction. J Am Coll Cardiol 1991; 17: 467–473.

76. Kloner RA: Adjuvant pharmacologic therapy for acute myocardial infarction. Hosp Formul 1991; 17: 467–473.

77. The TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–371.

78. Kloner RA, Alker K, Campbell C, Figures G, Eisenhauer A, Hale S: Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation 1989; 79: 1125–1136.

79. Ambrosio G, Weisman HF, Mansini JA, Becker LC: Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989; 80: 1846–1861.

80. Ku DD: Coronary vascular reactivity after myocardial ischemia. Science 1982; 218: 576–578.

81. Van Benthuysen KM, McMurty IF, Horwitz LD: Reperfusion after coronary occlusion in dogs impairs endothelium dependent relaxation to acetylcoline and augments contractile reactivity in vitro. J Clin Invest 1987; 79: 265–274.

82. Quillen JE, Selke FW, Brooks LA, Harrison DG: Ischemia–reperfusion impairs endothelium– dependent relaxation of coronary microvessels but does not affect large arteries. Circulation 1990; 82: 586–594.

83. Tsao PS, Aoki N, Lefer DJ, Johnson G, Lefer AM: Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990; 82: 1402–1412.

84. Schoefer J, Montz R, Mathey DG: Scintigraphic evidence of the “no reflow” phenomenon in humans beigns after coronary thrombolysis. J Am Coll Cardiol 1985; 5: 593–598.

85. Ito H, Tomooka T, Saki N: Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699–1705.

86. Kloner RA, Alker KJ: The effect of streptokinase on intramyocardial hemorrhage infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation 1984; 70: 513–521.

87. Roberts CS, Schoen FJ, Kloner RA: Effect of coronary reperfusion on myocardial hemorrhage and infarct healing. Am J Cardiol 1983; 52: 610–614.

88. Fishbein MC, Rit J, Lando V, Kanmatsuse R, Mercier JC, Ganz W: The relationship of vascular injury and myocardial hemorrhage to necrosis after reperfusion. Circulation 1980; 62: 1274–1279.

89. Gertz SD, Kalan JM, Kragel AN, Roberts WC, Braunwald E: The TIMI Investigators. Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. Am J Cardiol 1990; 65: 953–961.

90. Braunwald E, Kloner RA: The stunned myocardium: prolonged, post-ischemic ventricular dysfunction. Circulation 1982; 66:1146–1149.

91. Bolli R, Jeroudi MO, Patel BS: Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial “stunning” is a manifestation of reperfusion injury. Circ Res 1989; 65: 607–622.

92. Touchtone DA, Beller GA, Nygaard TW, Tedesco C, Kaul S: Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two-dimensional echocardiography. J Am Coll Cardiol 1989; 13: 1506–1513.

93. Sheehan FH, Doerr R, Schmith WG: Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12: 289–300.

94. Pfisterer M, Zuber M, Wenzel R, Burkart F: Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge? Eur Heart J 1991; 12: 214–217.

95. Nixon JV, Brown CN, Smitherman TC: Identification of transient and persistent segmental wall motion abnormalities in patients with unstable angina by two dimmensional echocardiography. Circulation 1982; 65: 1497–1503.

96. Wilson IC, Gardner TJ: Stunned myocardium in Cardiac Surgery. In: Kloner RA, Przyklenk K Ed. The stunned Myocardium: properties, mechanisms, and clinical manifestations. New York: Marcel Dekker, 1993: 379–399.

97. Wijns W, Serruys PW, Slager CJ: Effects of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional pressure radius relations. J Am Coll Cardiol 1986; 7: 455–463.

98. Klonner RA, Allen J, Cox TA, Zheng Y, Ruíz CF: Stunned left ventricular myocardium following exercise treadmill testing in coronary artery disease. Am J Cardiol 1991; 68: 629–634.

99. Arnold JMO, Braunwald E, Sandor T, Kloner RA: Inotropic stimulation of reperfused myocardium: effects on infarct size and myocardial function. J Am Coll Cardiol 1985; 6: 1026–1034.

100. Satler LF, Kent KM, Fox LM: The assessment of contractile reserve after thrombolytic therapy for acute myocardial infarction. Am Heart J 1986; 111: 821–825.

101. Manning AS, Hearse DJ: Reperfusion-induced arrhythmias: mechanisms and prevention. J Moll Cell Cardiol 1984; 16: 497–518.

102. Hale SL, Lange R, Alker KJ, Kloner RA: Correlates of reperfusion ventricular fibrillation in dogs. Am J Cardiol 1984; 53: 1397–1400.

103. Hagar JM, Hale SL, Kloner RA: Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 1991; 68: 61–68.

104. Hackett D, McKenna W, Davies G, Maseri A, Lowe T, Aber V: Reperfusion arrhythmias are rare during acute myocardial infarction and thrombolysis in man. Int J Cardiol 1990; 29: 205–213.

105. Burney RE, Walsh D, Kaplan LR, Fraser S, Tung B, Overmyer J: Reperfusion arrhythmia: myth or reality. Ann Emerg Med 1989; 18: 240-243.

106. Davies MJ, Thomas AC, Knapman PA, Hangartner JR: Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418–427.

107. Frink RJ, Rooney PA Jr, Trowbridge JO, Rose PJ: Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196–200.

108. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R: Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995; 92: 1701–1709.

109. Frink RJ, Ostrach LH, Rooney PA, Rose J: Coronary thrombosis, ulcerated atheroesclerotic plaques and platelet/fibrin microemboli in patients dying with acute coronary disease: a large autopsy study. J Clin Invest 1990; 2: 199–210.

110. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995; 92: 657–671.

111. Gassler JP, Topol EJ: Reperfusion Revisited: beyond TIMI 3 flow. Clin Cardiol 1999; 22: IV 20–IV 29.

112. Douglas JS Jr: Percutaneous intervention in patients with prior coronary bypass surgery. In: Topol EJ Ed. Textbook of Interventional Cardiology 3er. Ed. Philadelpia Pa: WB Saunders, 1999: 297–316.

113. El-Maraghi N, Genton E: The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death. Circulation 1980; 62: 936–944.

114. Folts JD, Crowell EB, Rowe GG: Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365–370.

115. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT: Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685–691.

116. Eidt JF, Allison P, Noble S, Ashton J, Godino P, McNatt J, et al: Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18–27.

117. Yao S-K, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, et al: ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium injured canine coronary arteries. Circ Res 1992; 70: 39–48.

118. Davies MJ: The composition of coronary-artery plaques. N Engl J Med 1997; 336: 1312–1313.

119. Heeschen C, van den Brand MJ, Hamm CW, Simmons ML, for the CAPTURE Investigators: Angiographic Findings in Patients with Refractory Unstable Angina According to Troponin T Status. Circulation 1999; 104: 1509–1514.

120. Zahi F, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G, et al: Noninvasive In Vivo Human Coronary Artery Lumen and Wall Imaging Using Black-Blood Magnetic Resonance Imaging. Circulation 2000; 102: 505–510.

121. Topol EJ, Leya F, Pinkerton CA, Withlow PL, Hofling B, Simonton CA, et al for the CAVEAT Study Group: A comparison of coronary angioplasty with directional atherectomy in patients with coronary artery disease. N Engl J Med 1993; 329: 221-227.

122. Holmes DR,Topol EJ, Califf RM, Leya F, Berberg PB, Talley JD, et al: For the CAVEAT-II Investigators: A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein graft lesions. Circulation 1995; 91: 1966–1974.

123. Eguchi H, Ikeda K, Murohara T, Yasukawa H, Haramaki N, Sakisaka S, Imaizumi K: Endothelial injuries of coronary arteries distal to thrombotic sites: role of adhesive interaction between endothelial P–selectin and leukocyte sialyl Lewis X. Circ Res 1999; 84: 525–535.

124. Laster SB, Ohnishi Y, Saffitz JE: Effects of reperfusion on ischemic right ventricular dysfunction: Disparate mechanisms of benefit related to duration of ischemia. Circulation 1994; 90: 1398-1409.

125. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621–1628.

126. Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, et al: Angiographic predictors of reocclusion after thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1995; 25: 582–589.

127. Tan WA, Moliterno DJ: TIMI flow and surrogate end points: What you see is not always what you get. Am Heart J 1998; 136: 570-573.

128. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, et al: The TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879–888.

129. Gibson CM, Goel M, Dotani I, Rizo M, McLean C, Martin NE et al: The post-PTCA TIMI frame count and mortality in RESTORE. Circulation 1996; 94 (suppl I): 1-85.

130. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al: Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125–130.

131. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, et al: Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765–772.

132. Vallejo E, Peña-Duque MA, Noroño O, Ban-Hayashi E, Gaspar J, Villavicencio R, Martínez RMA: Fenómeno de no–reflujo: incidencia y características clínicas en una serie de casos. Arch Inst Cardiol Méx 1998; 68: 247–252.

133. Califf RM, Abelmeguid A, Kuntz R, Popma JJ, Tardiff BE, Crenshaw B, et al: Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241–251.

134. Adgey AAJ, Mathew TP, Harbinson MT: Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Clin Cardiol 1999; 22: 257–265.

135. EPISTENT Investigators: Randomized controlled trial to assess safety of coronary stenting with use of abciximab. Lancet 1998; 352: 85–90.

136. Johansen O, Brekke M, Strommme JH, Valen V, Seljeflot I, Skjaeggestad O, Arnesen H: Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J 1998; 19: 112–117.

137. Reimers B, Lachin M, Cacciovillani L, Secchiero S, Ramondo A, Isabella G, et al: Troponin T, creatine kinasa MB mass and creatine kinasa isoform ratio in the detection of myocardial damage during non-surgical coronary revascularization. Int J Cardiol 1997; 60: 7–13.

138. Hamm CW, Heeschen C, Goldman B, Vahanian A, Adgey J, Miguel CM, et al for the CAPTURE Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to troponin T levels. N Engl J Med 1999; 340: 1623–1629.

139. Gasparone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, Gioffre PA: Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol 1998; 82: 515–518.

140. Morrow DA, Rifai N, Antman EM, Wiener DL, McCabe CH, Cannon CP, Braunwald E: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11-A substudy. J Am Coll Cardiol 1998; 31: 1460–1465.

141. Fox KAA: Acute coronary syndromes: presentation–clinical spectrum and management. Heart 2000; 84: 93–100.

142. Furman MI,Dauerman HL, Goldberg RJ, Yarzbeski J, Lessard D, Gore JM: Twenty–Two Year (1975 to 1997) Trens in the Incidence, In–ospital and long-term Case fatality Rates From Initial Q-wave and non-Q-wave Myocardial Infarction: A Multi–hospital, Community–Wide Perspective. J Am Coll Cardiol 2001; 37: 1571–1580.

143. Boersma E, Harrington RA, Moliterno DJ, White H, Teroux P, Van de Werf F, et al: Platelet glycoprotein IIb/III a inhibitors in acute coronary syndromes: a meta-analysis of all major randomized trials. Lancet 2002; 359: 189–198.

144. Bertrand ME, Simmons ML, Fox KAA: Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendation of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–1432.

145. Stone GW, Brodie BR, Griffin JJ, Morice MC, Constantini C, Overlie PA, et al on behalf of the Primary Angioplasty in Myocardial Infarction (PAMI) Investigators: Improved short-term outcomes of primary coronary stenting compared to primary balloon angioplasty in acute myocardial infarction at experienced centers: the PAMI study group experience. J Intervent Cardiol 1999; 12: 101–108.

146. Grines CL,Cox DA, Stone GW: Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999; 341: 1949–1956.

147. Brodie BR, Stuckey TD: Mechanical reperfusion therapy for acute myocardial Infarction: stent PAMI, ADMIRAL, CADILLAC and beyond. Heart 2002; 87: 191–192.

148. The GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/III a inhibition: The GUSTO V randomized trial. Lancet 2001; 357: 1905–1914.

149. Stone GW, Grines CL, Cox DA, García E, Tcheng JE, Griffin JJ et al: For the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) investigators: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–966.

150. The assessment of the safety and efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators: Efficacy and safety of tenecteplase in combination with enosaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001; 358: 605–613.

151. Montalescot G, Barragan p, Wittenbeg O, Ecollan P, Elhadad S, Villain P et al: For the ADMIRAL Investigators: Platelet glycoprotein IIb/III a inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903.

152. Neuman JF, Blasini R, Schmitt C, Eckhard A, Dirschinger J, Gawaz M et al: Effect of glycoprotein IIb/III a receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695–2701.

153. Frangogiannis NG, Smith WC, Entman ML: The inflammatory respose in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.

154. Entman ML, Smith CW: Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994; 9: 1301-1311.

155. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E: Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest 1973; 3: 599-607.

156. Roberts R, DeMello V, Sobel BE: Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976; 1: 204–206.

157. Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E: Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 1978; 1: 56-63.

158. Hill JH, Ward PA: The phlogistic role of C3 leukotactic fragment in myocardial infarcts of rats. J Exp Med 1971; 1: 885–890.

159. Pinckard RN, Olson MS, Giclas: Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 1975; 3: 740-750.

160. Gillum RF, Ingram DD, Makuc DM: White blood cell count, coronary heart disease, and death: the NHANES 1 epidemiologic follow-up study. Am Heart J 1993; 125: 855–863.

161. Friedman GD, Klastky AL, Siegelaub AB: The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974; 290: 1275-1278.

162. Frangi D, Gardinali M, Conciato L, Cafaro C, Pozzoni L, Agostino A: Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase. Circulation 1994; 89: 76–80.

163. Pietila KO, Harmoinen AP, Jokinitty J, Pasternack AI: Serum C–reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996; 17: 1345–1349.

164. Meijer CJ, Hack CE: C reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.

165. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average colesterol levels. Circulation 1998; 98: 839–844.

166. Juárez UH, Lasses LA, Martín RP, Luna JG, López MCR, Chuquiure EV, et al: Utilidad de la determinación cualitativa rápida de troponina T, fracción MB de creatinina fosfocinasa y mioglobina en los síndromes isquémicos coronarios agudos. Arch Inst Cardiol Méx 1998; 68: 473–481.

167. Saran RK, Been M, Furniss SS, Hawkins T, Reid DS: Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J 1990; 64: 113–117.

168. Barbash GI,Roth A, Hod H, Miller HI, Rath S, Har-Zahav Y, Modan M, et al: Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J. 1990; 64: 241–247.

169. Mauri F, Maggioni AP, Franzosi MG, Vita C, Santoro E, Santoro L et al: A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A GISSI-2 derived analysis. J Am Coll Cardiol 1994; 24: 600-607.

170. Dissmann R, Schröeder R, Busse U, Appel M, Brüggemann T, Jereczek M, Linderer T: Early assessment of outcome by segment analysis after thrombolytic therapy in acute myocardial infarction. Am Heart J 1994; 128: 851–857.

171. Schroeder RI, Wegscheider K, Schroeder K, Dissmann R, Meyer- Sabellek W: Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) Trial. J Am Coll Cardiol 1995; 26: 1657–1664.

172. Nakamura M, Tsunoda T, Wakatsuki T, Ui K, Degawa T, Yabuki S, Yamaguchi T: Distal coronary flow velocity immediately after direct angioplasty for acute myocardial infarction. Am Heart J 1996; 132: 251–257.

173. Iwakura K, Ito H, Takuchi S, Taniyama Y, Nakatsuchi Y, Negoro S, et al: Alteration in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996; 94: 1269–1275.

174. Vanhaecke J, Flameng W, Borgers M, Jang IK, Van de Werf F, DeGeest H: Evidence for decreased coronary flow reserve in viable postischemic myocardium. Cir Res 1990; 67: 1200–1210.

175. Brochet E, Czitrom D, Karila-Cohen D, Seknadji P, Faraggi M, Benamer H, et al: Early changes in myocardial perfusion patterns after myocardial infarction: relation with contractile reserve and functional recovery. J Am Coll Cardiol 1998; 32: 2011–1017.

176. Sakuma T,Hayashi Y, Sumii K, Imazu M, Yamakido M: Prediction of short-and intermediate–term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. J Am Coll Cardiol 1998; 32: 890–897.

177. Kondo M, Nakano A, Saito D, Shimono Y: Assessment of “microvascular no-reflow phenomenon” using technectium–99 m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998; 32: 898–903.

178. Maes A, Van der Werf, Nuyts J, Bormans G, Desmet W, Mortelmans L: Impaired myocardial tissue perfusion early after successful thrombolysis: impact on myocardial flow, metabolism and function at late follow-up. Circulation 1995; 92: 2070–2078.

179. Matsumara K, Jeremy RW, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97: 795–804.

180. Saeed M, Wendland M, Takehara Y, Masui T, Higgins CB: Reperfusion and irreversible myocardial injury: identification with a nonionic MR imaging contrast medium. Radiology 1992; 182: 675–683.

181. Lima JAC, Judd RM, Bazile A, Schulman SP, Atalar E, Zerhouni EA: Regional heterogeneity of human myocardial infarcts demonstrated by contrast enhanced MRI. Potential mechanisms. Circulation 1995; 92: 1117–1125.

182. Saed M, vanDijke CF, Wendland MF, Rosenau W, Higgins CB, Brash RC: Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction. J Magn Reson Imaging 1998; 8: 561–567.

183. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al: Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior myocardial infarction. Circulation 1996; 93: 1993–1999.

184. Agati L, Voci P, Bilotta F, Luongo R, Autore C, Penco M, et al: Influence of residual perfusion within the infarct zone on the natural history of left ventricular dysfunction after acute myocardial infarction: a myocardial contrast echocardiography study. J Am Coll Cardiol 1994; 34: 1336–1342.

185. Saeian K, Rhyne TL, Sagar Kb: Ultrasonic tissue characterization for diagnosis of acute myocardial infarction in the coronary care unit. Am J Cardiol 1994; 74: 1211–1215.

186. Lin LC, Wu CC, Ho YL: Ultrasonic tissue characterization for coronary care unit patients with acute myocardial infarction. Ultrasound Med Biol 1998; 24: 187–196.

187. Takiuchi S, Ito H, Iwakura K: Ultrasonic tissue characterization predicts myocardial viability in early stage of reperfused acute myocardial infarction. Circulation 1998; 97: 350–362.

188. Leistad E, Ohmori K, Peterson TA, Christensen G, DeMaria AN: Quantitative assessment of myocardial perfusion during graded coronary artery stenosis by intravenous myocardial contrast echocardiography. J Am Coll Cardiol 2001; 37: 624–631.

189. Hancock JE, Cooke JC, Chin DT, Monagham ML: Determination of successful reperfusion after thrombolysis for acute myocardial infarction. A noninvasive method using ultrasonic tissue characterization that can be applied clinically. Circulation 2002; 105: 157–161.

190. Antman EM, Giugliano RP, Gibson GM et al: For the TIMI 14 Investigators. abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720–2732.

191. Mizumura T, Nithipatikom K, Gross GL: Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine realize, and neutrophil infiltration in the dog. Cardiovasc Res 1995; 29: 482–489.

192. Sakata Y, Kodama K, lim YJ, Ishikura F, Hirayama A, Kitakaze M et al: Salutary effect of adjuntive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart 1997; 133: 616–621.

193. Galié N, Guarnieri C, Ussia GP, Zimarino M, Taini AM, Parlangeli R, et al: Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs. J Cardiovasc Pharmacol 1995; 26: 477–484.

194. Pieper GM, Gross GL: Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovasc Drugs Ther 1992; 6: 225–232.

195. Masazumi A, Lefer DJ, So T, DiPaula A, Aversano T, Becker LC: An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996; 27: 1278–1285.

196. Mahaffey KW, Puma JA, Barbagelata A, DiCarli MF, Leesar MA, Browe KF et al: For the AMISTAD Investigators: Adenosine as an adjunt to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The acute miocardial infarction study of adenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711–1720.

197. Ross AM, MolhoeK P, Lundergan C, Knudtson M, Draoui Y. Regalado L RN et al: Randomized comparison of enoxaparin, a low-molecular–weight heparin, with unfarctionated heparin adjuntive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HEART II). Circulation 2001; 104:648-652.

198. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand JP et al: For the ENTIRE–TIMI 23 Investigators: Enoxaparin as adjunctive antithrombin therapy for ST-Elevation myocardial infarction: Results of the ENTIRE–Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002;104: 1642–1648.

199. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, et al: For the PENTALYSE study: A synthetic factor–Xa inhibitor (ORG31540/sr9017A) as an adjunt to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716–1724.

200. Rogers WJ,Canto JG, Lambrew CT, Tiefenbrun AJ, Kinkaid B,Shoultz DA, et al: For the Investigators in the National Registry of Myocardial Infarction 1, 2 and 3: temporal Trends in the Treatment of over 1.5 Million Patients with Myocardial Infarction in the U.S from 1990 throught 1999. J Am Coll Cardiol 2000; 36: 2056-2063.

201. Topol EJ, Califf RM, George BS, Kereiakes DJ, Aboottsmith CW, Candela RJ et al: A randomized trial of immediate vs delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581–588.

202. Simmoons ML, Betriua A, Col J, Von Essen R, Lubsen J, Michel PL et al: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefits from immediate percutaneous coronary angioplasty. Lancet 1988; 1: 197–202.

203. The TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–627.

204. O´Neil WW, Weintraub R, Grines CL, Meany B, Brodie BR, Friedman HZ, et al: A prospective, placebo–controlled, randomized trial of intravenous streptokinase and angioplasty vs alone angioplasty therapy of acute myocardial infarction. Circulation 1992; 86: 1710–1717.

205. Antman EM, Giugliano RP, McCabe CH,Gibson M, Adgey AJJ, Ghali M, et al: Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 Trial (Abst). J Am Coll Cardiol 1998; 319( Suppl A ): 191 A.

206. Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, et al: Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (Gusto–4 Pilot) trial. J Am Coll Cardiol 2000; 36: 1989–1996.

207. Brodie BR, Stuckey TD, Hansen C, Muncy D: Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85: 13–18.

208. Vargas BJ, Peña DM, Roldan FJ, Romero AC, Espíndola ZN, Férez SS: Detection of right ventricular myocardial perfusion and contractil reserve by contrast echocardiography and low dose dobutamine in myocardial infarction after successful right coronary angioplasty. Arch Cardiol Méx 2002; 72: 49–52.

209. Lupi–Herrera E, Lasses LA, Cosio AJ, Chuquiure VE, Martínez SC, Ortíz P, et al: Acute right ventricular infarction: clinical spectrum, results of reperfusion therapy and short-term prognosis. Coron Artery Dis 2002;13: 57–64.